Mineralys presents post-hoc analysis linking BMI to enhanced BP reduction with lorundrostat

Mineralys Therapeutics, Inc.

Post-hoc analysis from Target-HTN Phase 2 trial: median systolic BP reduction of 32 mmHg in responder population.
Enhanced response proportional to BMI; modeled reduction ~12 mmHg at BMI 30 and ~19 mmHg at BMI 40 kg/m².
Statistically significant linear regression association between BMI and systolic BP reduction (BMI 22.5-40 kg/m²).
Advance-HTN pivotal trial enrolling; Phase 3 Launch-HTN trial expected to start before end of 2023.
Data supports obesity-associated aldosterone-dependent hypertensive endotype as predictor of response.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.